Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 15:28:e939750.
doi: 10.12659/AOT.939750.

Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ Transplantation

Joanna Raszeja-Wyszomirska  1 , Michał Macech  2 , Monika Kolanowska  3 , Marek Krawczyk  4 , Sławomir Nazarewski  2 , Anna Wójcicka  3 , Jolanta Małyszko  5
Affiliations
Review

Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ Transplantation

Joanna Raszeja-Wyszomirska et al. Ann Transplant. .

Abstract

A number types of extracellular DNA (eg, cell-free, cfDNA) circulate in human blood, including mitochondrial, transcriptome, and regulatory DNA, usually at low concentrations. Larger amounts of cfDNA appear in any inflammatory condition, including organ damage due to a variety of reasons. The role of cfDNA in solid organ transplantation is discussed in this review as a valuable additional tool in the standard of care of transplant patients. Post-transplant monitoring requires the use of high-quality biomarkers for early detection of graft damage or rejection to be able to apply early therapeutic intervention. CfDNA complements the traditional monitoring strategies, being a risk stratification tool and an important prognostic marker. However, improving the sensitivity and specificity of cfDNA detection is necessary to facilitate personalized patient management, warranting further research in terms of measurement, test standardization, and storage, processing, and shipping. A diagnostic test (Allosure, CareDx, Inc., Brisbane, CA) for kidney, heart and lung transplant patients is now commercially available, and validation for other organs (eg, liver) is pending. To date, donor-derived cfDNA in combination with other biomarkers appears to be a promising tool in graft rejection as it is minimally invasive, time-sensitive, and cost-effective. However, improvement of sensitivity and specificity is required to facilitate personalized patient management. Whether it could be an alternate to graft biopsy remains unclear.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Figures

Figure 1
Figure 1
Life-cycle of donor-derived cfDNA from peripheral blood. cfDNA – cell-free DNA (deoxyribonucleic acid).
Figure 2
Figure 2
Identification and quantification of cell-free DNA. cfDNA – cell-free DNA (deoxyribonucleic acid); NGS – next-generation sequencing.
See this image and copyright information in PMC

References

    1. Zhou M, Hara H, Dai Y, et al. Circulating organ-specific microRNAs serve as biomarkers in organ-specific diseases: Implications for organ allo- and xeno-transplantation. Int J Mol Sci. 2016;17(8):1232. - PMC - PubMed
    1. Wei L, Gong X, Martinez OM, Krams SM. Differential expression and functions of microRNAs in liver transplantation and potential use as non-invasive biomarkers. Transpl Immunol. 2013;29(1–4):123–29. - PMC - PubMed
    1. Gielis EM, Beirnaert C, Dendooven A, et al. Plasma donor-derived cell-free DNA kinetics after kidney transplantation using a single tube multiplex PCR assay. PLoS One. 2018;13(12):e0208207. - PMC - PubMed
    1. Zhao D, Zhou T, Luo Y, et al. Preliminary clinical experience applying donor-derived cell-free DNA to discern rejection in pediatric liver transplant recipients. Sci Rep. 2021;11(1):1138. - PMC - PubMed
    1. Zhu X, Ng HI, Xuan L, et al. Sequencing data of cell-free DNA fragments in living-related liver transplantation for inborn errors of metabolism. Data Brief. 2020;29:105183. - PMC - PubMed